Evidence map›Paper›PMID 41124679›Full record

ArticleJournal of medicinal chemistry2025

Exploiting the 2-(1,3,4,9-tetrahydropyrano[3,4-

Federica Blua, Francesca Boccato, Carola Buccellati, Patrizia Risè, Silvia Barbieri, Laura Castiglioni, Annika Balzulat, Barbara Rolando, Elisabetta Marini, Marta Balestra and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The crucial role of thromboxane AFrontiers in pharmacology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Federica BluaDepartment of Drug Science and Technology, University of Turin, Via P. Giuria 9, Turin 10125, Italy.ORCID 0000-0002-0306-9543
Francesca BoccatoDepartment of Drug Science and Technology, University of Turin, Via P. Giuria 9, Turin 10125, Italy.ORCID 0009-0001-3978-3490
Carola BuccellatiDepartment of Pharmaceutical Sciences, University of Milan, Milan 20122, Italy.
Patrizia RisèDepartment of Pharmaceutical Sciences, University of Milan, Milan 20122, Italy.
Silvia BarbieriCentro Cardiologico Monzino IRCCS, Milan 20138, Italy.
Laura CastiglioniDepartment of Pharmaceutical Sciences, University of Milan, Milan 20122, Italy.
Annika BalzulatInstitute of Pharmacology and Clinical Pharmacy, Goethe University, Max-von-Laue-Str. 9, Frankfurt am Main D-60438, Germany.
Barbara RolandoDepartment of Drug Science and Technology, University of Turin, Via P. Giuria 9, Turin 10125, Italy.ORCID 0000-0001-6138-1503
Elisabetta MariniDepartment of Drug Science and Technology, University of Turin, Via P. Giuria 9, Turin 10125, Italy.
Marta BalestraDepartment of Drug Science and Technology, University of Turin, Via P. Giuria 9, Turin 10125, Italy.
Maria Luisa IntrovigneDepartment of Drug Science and Technology, University of Turin, Via P. Giuria 9, Turin 10125, Italy.
Marta GiorgisDepartment of Drug Science and Technology, University of Turin, Via P. Giuria 9, Turin 10125, Italy.ORCID 0000-0002-3282-1220
Luigi SironiDepartment of Pharmaceutical Sciences, University of Milan, Milan 20122, Italy.
Stefania TacconelliDepartment of Neuroscience, Imaging and Clinical Sciences, "G. d'Annunzio" University, Chieti 66100, Italy.
Kerstin HiesingerInstitute of Pharmaceutical Chemistry, Goethe-University, Max-von-Laue-Str. 9, Frankfurt am Main D-60438, Germany.ORCID 0000-0001-5458-816X
Paola PatrignaniDepartment of Neuroscience, Imaging and Clinical Sciences, "G. d'Annunzio" University, Chieti 66100, Italy.
Achim SchmidtkoInstitute of Pharmacology and Clinical Pharmacy, Goethe University, Max-von-Laue-Str. 9, Frankfurt am Main D-60438, Germany.
Dieter SteinhilberInstitute of Pharmaceutical Chemistry, Goethe-University, Max-von-Laue-Str. 9, Frankfurt am Main D-60438, Germany.
Ewgenij ProschakInstitute of Pharmaceutical Chemistry, Goethe-University, Max-von-Laue-Str. 9, Frankfurt am Main D-60438, Germany.ORCID 0000-0003-1961-1859
Angelo SalaDepartment of Pharmaceutical Sciences, University of Milan, Milan 20122, Italy.
G Enrico RovatiDepartment of Pharmaceutical Sciences, University of Milan, Milan 20122, Italy.
Massimo BertinariaDepartment of Drug Science and Technology, University of Turin, Via P. Giuria 9, Turin 10125, Italy.ORCID 0000-0002-2533-5830

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of traditional nonsteroidal anti-inflammatory drugs (NSAIDs) and coxibs is effective for the treatment of inflammatory pain and chronic inflammatory conditions. However, their use is associated with enhanced risk of cardiovascular toxicity and thrombotic events, particularly for the latter. The vascular side effects of these drugs could be mitigated by pharmacological inhibition of the thromboxane A

Indexed as

Cyclooxygenase InhibitorsIndolesReceptors, ThromboxaneAnimalsHumansMaleMicePlatelet AggregationStructure-Activity RelationshipCyclooxygenase InhibitorsIndolesReceptors, Thromboxane

Identifiers

PMID41124679
PMCPMC12621201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.